ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves
ATL Ultrasound has received supplemental premarket approval (PMA) from the Food and Drug Administration to market a new scanhead, L12-5, for breast imaging applications on the company's HDI 3000 scanner. The transducer features a new design that improves near-field focus and image quality, according to the Bothell, WA, vendor. ATL has also received PMAs for breast imaging applications with its Ultramark 9 HDI and HDI 3000 systems.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.